Glaukos Corp
$ 120.52
0.86%
14 Apr - close price
- Market Cap 6,939,837,000 USD
- Current Price $ 120.52
- High / Low $ 122.00 / 119.50
- Stock P/E N/A
- Book Value 11.41
- EPS -3.27
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.26 %
- 52 Week High 130.23
- 52 Week Low 73.16
About
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.
Analyst Target Price
$138.92
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-17 | 2025-10-29 | 2025-07-30 | 2025-04-29 | 2025-02-19 | 2024-11-04 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-11-01 | 2023-08-02 | 2023-05-03 |
| Reported EPS | -0.9 | -0.16 | -0.24 | -0.22 | -0.4 | -0.28 | -0.52 | -0.7 | -0.63 | -0.5 | -0.55 | -0.59 |
| Estimated EPS | -0.21 | -0.26 | -0.26 | -0.3556 | -0.3885 | -0.48 | -0.51 | -0.57 | -0.55 | -0.55 | -0.55 | -0.58 |
| Surprise | -0.69 | 0.1 | 0.02 | 0.1356 | -0.0115 | 0.2 | -0.01 | -0.13 | -0.08 | 0.05 | 0 | -0.01 |
| Surprise Percentage | -328.5714% | 38.4615% | 7.6923% | 38.1327% | -2.9601% | 41.6667% | -1.9608% | -22.807% | -14.5455% | 9.0909% | 0% | -1.7241% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.3 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GKOS
2026-04-14 19:40:36
Glaukos Corp's Chief Development Officer, Tomas Navratil, sold 2,093 shares of common stock on April 10, 2026, fetching approximately $246,175. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026, with shares sold at prices ranging from $116.72 to $120.23. Following these sales, Navratil directly holds 90,370 shares, which includes unvested restricted stock units.
2026-04-11 01:09:46
Glaukos Corporation submitted a Form 144 notice revealing a proposed sale of common stock by an affiliate through Fidelity Brokerage Services LLC. The filing details past sales of 1,031 shares on March 16, 2026, for over $101,000, and also lists restricted stock vesting events occurring in late 2024 and early 2025. This notice provides transparency regarding potential future stock sales and identifies significant vesting schedules for company insiders.
2026-04-10 08:10:00
This article provides a detailed analysis of Glaukos Corporation (NASDAQ: GKOS), highlighting strong sentiment across all horizons with an overweight bias. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis indicating strong support and resistance levels. The analysis also points to an exceptional risk-reward short setup.
2026-04-08 11:10:06
Glaukos Corporation will release its first quarter 2026 financial results after market close on Wednesday, April 29, 2026. The company will host a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results. Interested parties can access the webcast via the company's website or participate in the call using provided dial-in numbers.
2026-04-07 10:40:27
Glaukos (GKOS) is gaining investor attention as it features its Epioxa corneal cross-linking treatment at the ASCRS annual meeting. The stock is currently trading at a discount to both analyst price targets and an intrinsic value model, with recent strong share price performance. The company's diversified pipeline in corneal health, glaucoma devices, and retinal programs is expected to drive future growth despite execution and reimbursement risks.
2026-04-07 04:40:28
Glaukos (GKOS) stock achieved a 5-day winning streak, increasing its value by 13% and boosting its market capitalization by $777 million to $6.7 billion. Despite this recent surge, the stock is considered "Unattractive" due to its "Very High valuation" and only "Moderate operating performance and financial condition." The article suggests that while the winning streak is notable, the market has already factored in this news, emphasizing the need for predictive signals for future gains.
